<DOC>
	<DOC>NCT03096795</DOC>
	<brief_summary>This is a Phase 1, randomised, blinded, placebo controlled, study designed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity response to single and multiple doses of MEDI3506.</brief_summary>
	<brief_title>Safety and Tolerability of MEDI3506 in Healthy Subjects and in Subjects With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>This is a Phase 1, randomised, blinded, placebo controlled, study designed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity response to single and multiple doses of MEDI3506 administered by either SC or IV routes. Part I: Single Ascending Doses in Healthy Subjects with a History of Mild Atopy and HDM Sensitivity Part II: Multiple Ascending Doses in Subjects with GOLD I-II COPD</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Inclusion Criteria Part I (SAD) 1. Healthy volunteers age 18 through 55 years at the time of consent. 2. Nonsmokers, healthy current smokers, and exsmokers are permitted. 3. Prebronchodilator FEV1 ≥80% Predicted . 4. BMI of 19.0 through 32.0 kg/m2 at screening. 5. Current history of mild atopy. 6. Positive response to protocolspecified skin prick testing with HDM allergen and or positive HDM specific IgE within 28 days of screening. Inclusion Criteria Part II (MAD) 1. Age 40 through 80 years at the time of screening. 2. BMI of 19.0 through 35.0 kg/m2 at screening. 3. Normal echocardiographic assessment within a year prior to randomisation 4. Documented history of COPD with a postbronchodilator FEV1/FVC &lt;0.70 and a postbronchodilator FEV1 ≥50% predicted at screening. 5. Clinically stable and free from an acute exacerbation of COPD for 8 weeks prior to Day 1 6. Current smoker with a tobacco history of ≥10 packyears Exclusion Criteria Part I (SAD) 1. Concurrent enrollment in another clinical study involving an investigational treatment. 2. Received administration of and investigational drug or participated in a device trial within months, prior to screening (Visit 1) 3. Subject is a participating investigator, subinvestigator, study coordinator or employee of the participating site, or is a firstdegree relative of the aforementioned. 4. Any active medical or psychiatric condition or other reason which, in the opinion of the investigator or medical monitor, may compromise the safety of the subject in the study or interfere with evaluation of the investigational product or reduce the subject's ability to participate in the study. 5. Any clinically relevant abnormal findings on physical examination of the cardiovascular system including ECG and vital signs at screening or randomization 6. Abnormal vital signs, after 10 minutes supine rest Exclusion Criteria Part II (MAD) 1. Participation in an investigational drug or device trial within 30 days or 5 halflives, whichever time period is longer, prior to screening. 2. Subject is a participating investigator, subinvestigator, study coordinator, or employee of the participating site, or is a firstdegree relative of the aforementioned. 3. Any active medical or psychiatric condition or other reason that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results. This includes, but is not limited to: 4. Uncontrolled diabetes 5. Hypertension during the screening period 6. Significant or unstable ischaemic heart disease, arrhythmia, cardiomyopathy, heart failure 7. Clinically significant Aortic stenosis 8. Pulmonary Arterial Hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MEDI3506</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>